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The use of bisphosphonates in the management of bone involvement from solid tumours and haematologi-
cal malignancies – a European survey
Bone metastases in patients with solid tumours (ST) and bone lesions in patients with haematological
malignancies (HM) are common. Associated skeletal-related events (SREs) cause severe pain, reduced
quality of life and place a burden on health care resources. Bone-targeted agents can reduce the risk of SREs.
We evaluated the management of bone metastasis/lesions in five European countries (France, Germany,
Italy, Spain and the UK) by an observational chart audit. In total, 881 physicians completed brief
questionnaires on 17 193 patients during the observation period, and detailed questionnaires for a further
9303 individuals. Patient cases were weighted according to the probability of inclusion. Although a large
proportion of patients with bone metastases/lesions were receiving bisphosphonates, many had their
treatment stopped (ST, 19%; HM, 36%) or will never be treated (ST, 18%; HM, 13%). The results were
generally similar across the countries, although German patients were more likely to have asymptomatic
bone lesions detected during routine imaging. In conclusion, many patients who could benefit from bone-
targeted agents do not receive bisphosphonates and many have their treatment stopped when they could
benefit from continued treatment. Developing treatment guidelines, educating physicians and increasing
the availability of new agents could benefit patients and reduce costs.
Keywords: bisphosphonate, bone metastases, bone-targeted agent, haematological malignancy, skele-
tal-related event, solid tumour.
INTRODUCTION
Bone complications are common in patients with
advanced solid tumours (ST) and haematological malig-
nancies (HM; Coleman 2001). Skeletal metastases are
most frequently found in individuals with advanced breast
cancer or prostate cancer, affecting 65–90% of patients,
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and bone lesions are present in up to 96% of patients with
newly diagnosed multiple myeloma (Coleman 2001; Kyle
et al. 2003; Parker et al. 2013). Bone metastases also occur
frequently in patients with other ST such as advanced
lung and kidney cancer, but are rare in patients with gas-
trointestinal tumours. This pattern of occurrence may
result from the route of blood drainage from the breast and
pelvis to the skeleton. In addition, interactions between
cancer cells and the bone marrow stroma may result in
the promotion of secondary tumour growth (Coleman
2001).
As the treatment of cancer improves and patients live
longer, the prevalence of bone involvement is predicted to
rise. Bone metastases and lesions are associated with sev-
ere pain and debilitating skeletal-related events (SREs),
which include pathologic fractures, spinal cord compres-
sion and the need for therapeutic radiation or surgery to
bone (Coleman 2001; Ibrahim et al. 2013). SREs are associ-
ated with increased mortality (Saad et al. 2007b; Norgaard
et al. 2010) and reduced quality of life (Weinfurt et al.
2004, 2005; Depuy et al. 2007; Costa et al. 2008; von
Moos et al. 2013), and place a considerable burden on hos-
pital resources (Delea et al. 2006; Lage et al. 2008; Pockett
et al. 2010; Hechmati et al. 2011; von Moos et al. 2013;
Hoefeler et al. 2014; Body et al. 2015). Therefore, the
effective management of metastatic bone disease and bone
lesions is of increasing importance in order to improve
clinical outcomes and the quality of life of patients. This
management requires a multidisciplinary approach
involving specialists in areas such as oncology, radiother-
apy, orthopaedics, nursing and palliative care (Ibrahim
et al. 2009, 2013).
Bisphosphonates are bone-targeted drugs that have been
shown to reduce the risk of SREs in patients with bone
metastases secondary to ST (Body 2003; Lipton 2007) and
in patients with multiple myeloma and bone involvement
(Berenson et al. 1996; Rosen et al. 2003). The use of bis-
phosphonates, particularly nitrogen-containing agents
such as pamidronate and zoledronate, is associated with
side effects which, although rare, should be considered
when initiating treatment. Osteonecrosis of the jaw (Woo
et al. 2006; EMA 2015a) and a modest risk of renal toxicity
(<10%) (Conte & Guarneri 2004) have been associated
with bisphosphonate use. The benefit–risk ratio should be
taken into consideration before initiating bisphosphonate
treatment and careful monitoring should be carried out
once treatment has commenced. The risks are typically
outweighed by the fact that bone-targeted agents can delay
the onset of the first and subsequent SREs (Lipton 2007;
Saad et al. 2007a), therefore the clinical benefit for
patients with bone metastases or lesions is considerable.
The aim of this patient chart survey was to assess the
management of bone metastases and lesions in patients
with ST and HM across five European countries, in order
to evaluate the use of bisphosphonates and to identify any
barriers to their use.
PATIENTS AND METHODS
This was an observational chart audit performed over
2–3 weeks in March 2010 in France, Germany, Italy, Spain
and the UK. In total, 881 physicians (307 oncologists, 164
haematologists, 196 urologists, 120 oncological haematol-
ogists, 41 pulmonologists, 31 gynaecologists, 12 radiation
oncologists and 10 internists) who treated patients with
advanced cancer were selected to form a representative
sample. Eligible physicians had to manage at least five
patients per week with advanced cancer involving bone.
The number of patients intended to be included in this
survey was 16 500.
The audit was divided into two parts that were com-
pleted concurrently by participating physicians. In the
first part, physicians completed a brief questionnaire
(Appendix 1) for every patient they saw with bone metas-
tases associated with ST (prostate cancer, breast cancer,
lung cancer, renal cell carcinoma, bladder cancer, colorec-
tal cancer or other ST), or with bone lesions associated
with HM [multiple myeloma, or non-Hodgkin lymphoma
(NHL)], and for all additional patients who were being
treated with a bisphosphonate for cancer-related reasons.
Disease was staged using a scale of I–IV (Ann Arbor stag-
ing system) in patients with ST or NHL, and a scale of I to
III in patients with multiple myeloma (Durie and Salmon
staging system). The observation period was 2–3 weeks, as
dictated by the caseload of the physician. In the second
part of the audit, physicians completed a detailed ques-
tionnaire (Appendix 2) on the next 11 consecutive
patients that they saw who met the pre-defined criteria.
These criteria were: the first six patients treated with bis-
phosphonates for cancer-related reasons (to treat or pre-
vent bone lesions); the first two patients who had
discontinued cancer-related treatment with bisphospho-
nates; and the first three patients with bone involvement
who had never received bisphosphonates. Data on these
patients were collected retrospectively via chart survey.
The frequency with which a patient visits their physi-
cian is usually determined by the type of cancer they are
being treated for. Therefore, in order to avoid an under-
estimation or over-estimation of the prevalence of differ-
ent cancers, cases from the first part of the audit were
weighted according to the probability of inclusion in the
study. The weighting coefficient was estimated based on
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the consultation frequency and the length of the observa-
tion period (i.e. the probability of the patient seeing the
physician within the observation period; patients seeing
the physician more frequently, e.g. those receiving
chemotherapy every 3 weeks, were more likely to be
included than those seeing the physician less frequently,
e.g. those taking oral targeted therapy). To correct for any
recruitment bias, data were weighted by the date of next
consultation, with patients returning sooner allocated a
lower coefficient than those returning later.
In each country, the evaluation an individual physi-
cian’s caseload obtained in the first part of the audit was
also used to weight each detailed patient case appropri-
ately in the second part. This ensured that the representa-
tive proportions of the patient populations according to
treatment status (currently treated with bisphosphonates,
previously treated, treatment planned, or will never be
treated) measured in the first part of the audit were main-
tained in the second part, and in any analysis based on data
from the detailed questionnaires.
RESULTS
Physicians and patients
In the first part of the audit (brief questionnaires), the 881
participating physicians provided data on 17 193 patients.
These data showed that patient characteristics were lar-
gely consistent across the five countries (Table 1). The
median ages of patients in each malignancy group were
similar (ST, 67.7 years; HM, 67.5 years). For patients with
ST, the youngest were in Germany (median age,
62.6 years) and the oldest in Italy (70.3 years). The median
age of patients with HM was consistent across countries
(64.3–68.3 years) (Table 1).
Detailed data were provided for 9303 patients who
were included in the second part of the audit. From these
questionnaires, the most common cancer types associ-
ated with bone metastases or lesions (n = 8768) were
prostate cancer, breast cancer, lung cancer and multiple
myeloma (Table 2). In Germany, there was a slightly
higher proportion of patients with bone metastases who
had lung cancer (20%) than in the other countries (Spain,
13%; France, 12%; Italy, 9%, UK, 8%; Table 2). Eastern
Cooperative Oncology Group (ECOG) status and life
expectancy (according to the treating physician’s opinion)
in patients with bone metastases or lesions are listed in
Table 3. Most patients had an ECOG status of 1 (ST,
47%; HM, 38%) or 2 (ST, 27%; HM, 22%). Only 1% of
all patients had an ECOG status of 4. Most patients with
ST (82%) and HM (96%) had a life expectancy of 1 year
or more (Table 3). T
ab
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Data from the detailed questionnaire showed that dis-
ease staging at initial diagnosis was consistent across
countries (data not shown). Almost half of the 7558
patients with ST were diagnosed with stage IV disease
(stage I, 5%; stage II, 23%; stage III, 25%; stage IV, 46%).
Similarly, for patients with NHL (n = 227), most patients
were diagnosed with the latest stage disease (stage I, 3%;
stage II, 10%; stage 3, 13%; stage IV, 74%). Of the 1528
patients with multiple myeloma, most were diagnosed
with stage III disease (stage I, 10%; stage 2, 18%, stage III,
71%).
Detection of bone metastases/lesions
From the detailed questionnaire, almost all patients had
bone metastases or bone lesions (94%; n = 8768). Of these
patients, 82% had ST and 17% had HM (Table 2). The lar-
gest proportion of patients with bone involvement had
their metastases or lesions identified during staging at
diagnosis of the primary cancer (ST, 38%; HM, 65%) or as
a result of bone pain (ST, 35%; HM, 36%) (Table 4). Ger-
many was an exception because routine screening during
follow-up was the main method of detection of bone
metastases and lesions in patients with ST (41%). Further-
more, metastases or lesions were less frequently identified
in patients with ST as a result of bone pain in Germany
(20%) than in other countries (range, 34–48%) (Table 4).
Across most countries, patients were most likely to have
bone metastases or lesions identified at multiple dissemi-
nated sites (ST, 36%; HM, 48%; Fig. 1). Again, Germany
was the exception because patients with ST were more
likely to have solitary bone metastasis at diagnosis (44%)
than to have metastases at multiple disseminated sites
(27%). The circumstances of diagnosis of bone lesions in
patients with HM in Germany were similar to those in
other countries.
Treatment of bone metastases/lesions
In the first part of the audit (brief questionnaire), most
patients had bone metastases or lesions at the time of con-
sultation (86%). Although a large proportion of these
patients were currently receiving bisphosphonate treat-
ment (ST, 68%; HM, 60%), many had their treatment
Table 2. Type of cancer in patients with bone metastases/lesions: data from the detailed questionnaire
Cancer type (%) Total (N = 8768) France (n = 1665) Germany (n = 2326) Italy (n = 1680) Spain (n = 1534) UK (n = 1563)
Prostate cancer 31 33 20 35 37 34
Breast cancer 22 22 21 21 19 27
Lung cancer 13 12 20 9 13 8
Renal cell carcinoma 7 6 10 5 5 7
Bladder cancer 4 2 9 3 4 2
Colorectal cancer 3 1 7 2 2 2
Other solid tumour 2 3 3 2 2 1
Multiple myeloma 15 18 9 20 16 16
Non-Hodgkin
lymphoma
2 3 3 3 2 1
HM, haematological malignancy; ST, solid tumour.
Table 3. ECOG performance status and life expectancy (according to treating physician’s opinion) in patients with bone metastases/
lesions: data from the detailed questionnaire
Total
(N = 8768)
France
(n = 1665)
Germany
(n = 2326)
Italy
(n = 1680)
Spain
(n = 1534)
UK
(n = 1563)
ST HM ST HM ST HM ST HM ST HM ST HM
Performance status (%)
ECOG 0 16 31 16 38 9 9 25 42 18 20 15 40
ECOG 1 47 38 48 36 52 54 40 33 47 31 45 40
ECOG 2 27 22 28 18 29 34 25 19 26 30 26 14
ECOG 3 9 6 7 6 9 2 8 5 7 15 12 4
ECOG 4 1 1 1 3 1 0 1 1 2 1 1 2
Life expectancy (%)
<1 year 17 4 15 3 10 6 20 5 24 3 22 4
1–3 years 46 34 42 25 43 41 47 33 48 50 53 26
>3 years 36 60 42 69 47 52 33 62 27 47 26 69
ECOG, Eastern Cooperative Oncology Group; HM, haematological malignancy; ST, solid tumour.
4 © 2016 The Authors. European Journal of Cancer Care Published by John Wiley & Sons Ltd.
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stopped (ST, 19%; HM, 36%) or would never receive bis-
phosphonates (ST, 18%; HM, 13%). Treatment with bis-
phosphonates was planned in a small proportion of
patients (ST, 10%; HM, 7%) (Fig. 2).
Almost one-fifth of patients with ST and bone metas-
tases or lesions were expected never to receive bisphos-
phonates (ST, 18%; HM, 13%) although most patients in
this group had a moderate-to-high estimated risk of
Table 4. Circumstances of discovery of bone metastases and lesions, by malignancy type and by country: data from the detailed
questionnaire
Response given (%)
Total
(N = 8768)
France
(n = 1665)
Germany
(n = 2326)
Italy
(n = 1680)
Spain
(n = 1534)
UK
(n = 1563)
ST HM ST HM ST HM ST HM ST HM ST HM
Staging at diagnosis 38 65 41 74 31 75 39 57 37 52 45 68
Bone pain 35 36 48 52 20 7 34 37 37 46 42 34
Routine metastases screening 25 5 14 2 41 12 30 6 21 7 6 1
Investigation following an event* 7 18 9 20 5 10 6 23 5 20 9 13
Hypercalcaemia 5 9 6 15 3 1 4 7 5 9 6 13
Accidental discovery 5 3 5 1 5 1 5 3 6 9 4 1
Other† 3 0 6 0 0 0 3 0 4 0 3 0
HM, haematological malignancy; PSA, prostate-specific antigen; ST, solid tumour.
*Events included confirmed or suspected pathologic fracture or spinal compression.
†Including increase in tumour markers (e.g. PSA), check on spread of metastases/restaging for any metastases, extensive examination
after finding lumps, worsening of general condition and pain. Investigators could give more than one response.
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Figure 1. Description of bone metastases
and lesions at discovery, by malignancy
type and by country in patients with (A)
solid tumours and (B) haematological
malignancies: data from the detailed
questionnaire. The difference between
multiple disseminated sites and multiple
sites was subjective and determined by
the treating physician.
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developing an SRE (evaluated by the physician) (data not
shown). The proportions of patients with ST who were
expected never to receive bisphosphonates were reason-
ably consistent across countries with the exception of the
UK, where almost twice as many patients were expected
never to receive bisphosphonates (26%) as in other coun-
tries (range, 13–14%). Zoledronic acid was the most com-
monly used bisphosphonate in both malignancy types
(ST, 75%; HM, 66%). Pamidronate, clodronate and iban-
dronate were the next most common bisphosphonates and
their use ranged from 5% to 9% in patients with ST, and
from 4% to 14% in those with HM.
The main rationales for bisphosphonate treatment were:
to prevent SREs (ST, 71%; HM, 66%), to treat or prevent
pain (ST, 55%; HM, 42%), to prevent the development of
new bone metastases or lesions (ST, 38%; HM, 47%) and
to treat bone metastases or lesions at the original site (ST,
38%; HM, 36%) (Table 5). Compared with other coun-
tries, Germany reported more frequently that the rationale
for bisphosphonate use was based on the assumption that
they prevent new metastases or lesions (ST, 69%; HM,
67%), whereas in France, this reason was given infre-
quently (ST, 15%; HM, 33%) (Table 5).
The most common reason for discontinuing bisphos-
phonate treatment was the ‘end of treatment as planned’
(ST, 51%; HM, 72%, Table 6). Overall, patients were most
often treated with bisphosphonates for a duration of
13–24 months (ST, 37%; HM, 38%) (Table 7). In Ger-
many, a larger proportion of patients were treated with
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Figure 2. Bisphosphonate treatment rates in patients with bone
metastases/lesions across all countries: data from the brief ques-
tionnaire (n = 14 871).
Table 5. Reason for initial treatment with bisphosphonates in patients with bone metastases/lesions, by malignancy type and by
country: data from the detailed questionnaire
Response given (%)
Total
(N = 7368)
France
(n = 1483)
Germany
(n = 1973)
Italy
(n = 1427)
Spain
(n = 1325)
UK
(n = 1160)
ST HM ST HM ST HM ST HM ST HM ST HM
Prevent SREs 71 66 66 67 84 87 64 62 65 57 67 61
Treat/prevent pain 55 42 57 44 68 72 43 32 49 42 48 29
Prevent new bone metastases/bone lesions 38 47 15 33 69 67 32 47 26 42 26 49
Treat bone metastases/lesion at original site(s) 38 36 30 26 59 47 36 38 19 43 33 31
Patient’s disease has high risk factors 5 7 9 20 1 0 5 6 4 3 10 4
End of anti-tumour treatment 1 1 1 0 0 1 2 3 3 1 2 0
Other 1 2 3 3 0 2 1 0 0 0 2 4
HM, haematological malignancy; ST, solid tumour.
Investigators could give more than one response.
Table 6. Reasons for discontinuation of bisphosphonates in patients with bone metastases/lesions, by malignancy type and by
country: data from the detailed questionnaire
Response given (%)
Total
(N = 1838)
France
(n = 392)
Germany
(n = 516)
Italy
(n = 363)
Spain
(n = 309)
UK
(n = 258)
ST HM ST HM ST HM ST HM ST HM ST HM
End of treatment as planned* 51 72 48 77 67 60 38 68 44 85 36 56
Toxicity 16 11 25 7 7 18 20 15 34 9 3 5
Risk of toxicity 7 6 10 3 9 17 5 9 5 1 6 9
Lack of efficacy† 12 4 7 7 13 9 20 1 7 1 10 3
Contraindication due to concomitant treatment 3 1 1 1 3 8 0 0 3 1 1 0
Other 9 7 18 11 4 10 16 6 5 0 7 8
Investigators could give more than one response.
HM, haematological malignancy; ST, solid tumour.
*Planned duration of treatment was determined by treating physician.
†As determined by treating physician.
6 © 2016 The Authors. European Journal of Cancer Care Published by John Wiley & Sons Ltd.
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bisphosphonates for 13–24 months (ST, 55%; HM, 51%)
than in the other countries [range, 9–37% (ST); 33–43%
(HM)] (Table 7). Some patients who had their treatment
stopped as planned were treated for only 6 months or less
(ST, 15%; HM, 18%) (Table 8). Of those who had their
treatment stopped owing to reaching the end of their
planned treatment period, there was considerable varia-
tion between the countries: only 3% of patients with ST
in Germany received bisphosphonates for 6 months or
less, in contrast to 51% in the UK (Table 8).
Bisphosphonate treatment was often delayed in all
countries except Germany (data not shown). Themain jus-
tification for delaying bisphosphonate treatment was that
bone metastases and lesions were controlled by initial
anti-tumour therapy (ST, 57%; HM, 53%) (Fig. 3). This
reason was particularly common in the UK (ST, 86%; HM,
66%). This justification was used fairly consistently in the
other countries for patients with ST or multiple myeloma,
but was used more frequently for patients with NHL
(71%). Across all countries, the most common cancer
treatments at diagnosis for patients with ST were hor-
mone therapy (42%), surgery (40%), and chemotherapy
(37%). Most patients with HM (77%) received chemother-
apy as an initial treatment for their cancer (Table S1).
Owing to the risk of side effects associated with bispho-
sphonates, it is perhaps unsurprising that concern over
safety was frequently given as a reason for treatment delay
(ST, 31%; HM, 31%). This was the most common reason
given in Germany (ST, 63%; HM, 64%). The next most
common reasons for treatment delay were patient profile
(e.g. poor performance status or short life expectancy)
(ST, 30%; HM, 18%) and bone lesion characteristics (e.g.
pain controlled with analgesics and the risk of SREs) (ST,
28%; HM, 21%) (Fig. 3). Patient profile was more com-
monly used as a justification for delaying treatment in
patients with lung cancer (50%), bladder cancer (48%) and
other ST (47%) than for patients with other types of malig-
nancy.
The most common reasons given by physicians predict-
ing that patients would never receive bisphosphonate
treatment were: short life expectancy (ST, 41%; HM,
21%), renal issues (ST, 36%; HM, 39%) and poor benefit–
risk ratio (ST, 34%; HM, 31%) (Table 9). These reasons
were commonly given in all the countries studied,
although their relative frequencies varied. For example,
renal complications were the most common reason for not
administering bisphosphonates in Germany (ST, 55%;
HM, 66%), whereas this reason was recorded much less
frequently in the UK (ST, 18%; HM, 22%). More than one-
third of patients who took part in the second part of the
audit had renal complications (ST, 31%; HM, 32%) and
these proportions were consistent with observations in
both Germany and the UK.
Skeletal-related events
At the timepoint of this survey, many patients had experi-
enced at least one SRE, irrespective of the time of their
Table 7. Duration of treatment with bisphosphonates for those patients with bone metastases/lesions who had treatment stopped, by
malignancy type and by country: data from the detailed questionnaire
Treatment duration (%)
Total
(N = 947)
France
(n = 220)
Germany
(n = 329)
Italy
(n = 167)
Spain
(n = 155) UK (n = 74)
ST HM ST HM ST HM ST HM ST HM ST HM
≤6 months 15 18 27 19 3 0 11 25 26 15 51 21
7–12 months 18 21 18 29 12 0 14 11 36 25 37 34
13–24 months 52 41 33 42 70 65 58 31 28 48 6 12
>24 months 14 17 20 5 15 35 18 30 10 11 4 33
Unknown 1 3 2 6 0 0 0 4 0 0 3 1
Table 8. Duration of treatment with bisphosphonates for those patients with bone metastases/lesions who had treatment stopped
owing to end of planned treatment, by malignancy type and by country: data from the detailed questionnaire
Treatment duration (%)
Total
(N = 1806)
France
(n = 381)
Germany
(n = 516)
Italy
(n = 357)
Spain
(n = 306)
UK
(n = 246)
ST HM ST HM ST HM ST HM ST HM ST HM
≤6 months 28 20 37 23 14 4 24 23 33 20 50 20
7–12 months 21 22 19 29 17 7 19 16 30 28 26 16
13–24 months 37 38 29 39 55 51 36 31 28 43 9 33
>24 months 14 16 13 4 14 39 18 23 10 9 13 27
Unknown 1 4 2 4 0 0 2 7 0 0 2 4
HM, haematological malignancy; ST, solid tumour.
© 2016 The Authors. European Journal of Cancer Care Published by John Wiley & Sons Ltd. 7
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cancer diagnosis (ST, 22%; HM, 41%) (Table 10). The
most common SRE in patients with ST was radiation to
bone, and for those with HM it was pathological fracture.
Patients who were currently treated or had previously
been treated with bisphosphonates were most likely to
have experienced an SRE. In those who were expected to
receive bisphosphonates in the future, the prevalence of
SREs was 10% and 32% among patients with ST and HM
respectively. Of those patients who were expected never
to receive bisphosphonate treatment (12% of patients
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Figure 3. Reasons for delaying bisphospho-
nate treatment in patients with bone
metastases/lesions, by malignancy type
and by country in patients with (A) solid
tumours and (B) haematological
malignancies: data from the detailed
questionnaire. Anti-tumour treatment
included radiotherapy, hormonal therapy,
chemotherapy and targeted therapy. Safety
concerns included existing renal
impairment, to avoid renal deterioration
and dental health issues. Patient profile
included poor performance status and
short life expectancy prognosis. Bone
lesion characteristics included low risk of
fracture/compression, no pain and pain
controlled by analgesics. Investigators
could givemore than one response.
Table 9. Reasons why patients with bone metastases/lesions would never receive bisphosphonates, by malignancy type and by
country: data from the detailed questionnaire
Reason given (%)
Total
(N = 1360)
France
(n = 250)
Germany
(n = 304)
Italy
(n = 226)
Spain
(n = 216)
UK
(n = 364)
ST HM ST HM ST HM ST HM ST HM ST HM
Renal issue 36 39 46 21 55 66 34 59 33 32 18 22
Dental health issue 9 10 9 8 20 12 9 15 3 12 2 1
Poor benefit–risk ratio 34 31 43 40 29 23 38 21 25 28 36 42
Patient refusal 6 3 7 2 10 2 6 8 4 0 5 5
Short life expectancy 41 21 38 13 41 14 32 17 52 42 41 22
Pain from BM controlled by analgesics/opioids 14 11 19 21 14 12 8 4 9 5 18 4
Other 5 17 7 35 3 17 5 18 9 10 4 0
BM, bone metastases/lesions; HM, haematological malignancy; ST, solid tumour.
Investigators could give more than one response.
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with ST and 7% of those with HM), a large proportion had
received radiation to bone and/or experienced a pathologi-
cal fracture.
DISCUSSION
This large-scale chart audit with a robust methodology
provides insight into the real-life management of patients
with bone metastases or bone lesions in five European
countries. These data suggest that approximately 80% of
patients with bone metastases or lesions receive treat-
ment with bisphosphonates during the course of their dis-
ease, and although most of these patients were receiving
treatment at the time of this survey, there were patients
who may benefit from initiating, or continuing treatment.
In general, the findings for patients with ST were consis-
tent with those for patients with HM. Bone metastases
and lesions were most likely to be discovered during dis-
ease staging at diagnosis, and most patients had multiple
metastases or lesions. The major difference between
malignancy types was that fewer patients with ST than
those with HM were currently being treated, or had treat-
ment planned, with bisphosphonates. This may be due to
a combination of patient characteristics, such as poor per-
formance status or life expectancy prognosis, and a lack of
consensus in guideline recommendations. Bone pathology
is one of the defining features of multiple myeloma (Raje
et al. 2014). One study found that 79% of patients with
multiple myeloma had bone abnormalities and 67% of
patients had lytic bone lesions. In addition, more than half
of patients experienced bone pain (Kyle et al. 2003; Raje
et al. 2014). Bisphosphonates are therefore recommended
in several guidelines to manage pain and control SREs in
patients with multiple myeloma (Berenson et al. 2002;
Harrouseau et al. 2005). This appears to be reflected in our
study where more patients with HM than with ST were
receiving bisphosphonate treatment. Bone involvement in
breast cancer and prostate cancer is also common, with
the reported incidence being as high as 75–90% (Coleman
2001; Parker et al. 2013). Therefore, it was surprising that
over one-third of patients with ST were not receiving bis-
phosphonate treatment. Bone-targeted agents are recom-
mended by several guidelines for patients with ST,
therefore these results highlight differences between
guidelines and real-life use of bisphosphonates. This also
suggests that there are patients who could benefit from,
but are not receiving, bisphosphonates.
Approximately, half of the patients in our study
received bisphosphonate treatment for 1 year or more.
The majority of patients had their bisphosphonate therapy
stopped owing to the end of planned treatment and approx-
imately one-fifth of those individuals received treatment
for only 6 months or less. This was more common in the
UK, with the majority of patients with ST receiving bis-
phosphonate treatment for 6 months or less. The opti-
mum duration of bone-targeted therapy is unknown
although pivotal studies for the bisphosphonates were
generally conducted over 2 years and clinical benefit was
observed throughout this time-frame (Berenson et al.
2002). Continued treatment for at least 2 years could be
beneficial because bone-targeted therapy delays not only
first but also subsequent SREs (Saad et al. 2007a; Stopeck
et al. 2010; Fizazi et al. 2011; Henry et al. 2011). A pla-
cebo-controlled study of patients with prostate cancer
showed that in the second year of bisphosphonate treat-
ment, the risk of SREs continued to be substantially
reduced, with a risk reduction of 53% compared with pla-
cebo (Saad et al. 2007a). The same study also demonstrated
that treatment significantly reduced the risk of further
SREs in patients who have already experienced one event.
Furthermore, a significantly reduced risk of SREs has been
reported in patients with breast cancer during the second
year of bisphosphonate treatment (Aapro et al. 2010).
Perhaps, owing to the lack of information and consensus
in the guidelines regarding optimal duration of treatment,
effective medication for patients with bone metastases or
Table 10. Skeletal-related events in patients with bone metastases/lesions by malignancy type and by bisphosphonate treatment
status: data from the detailed questionnaire
All BM
patients
(N = 8768)
Currently
treated
(n = 5133)
Previously
treated
(n = 1699)
Treatment
planned
(n = 575)
Will never be
treated
(n = 1361)
ST HM ST HM ST HM ST HM ST HM
All SREs (%) 22 41 21 45 25 40 10 32 16 25
n 1592 646 1043 386 303 188 51 19 189 47
Radiotherapy to bone 62 28 63 27 63 28 57 20 55 47
Pathologic fracture 30 62 31 63 29 62 31 74 30 53
Spinal cord compression 15 19 14 18 16 24 12 16 20 9
Surgery to bone 7 8 6 9 6 7 4 16 12 0
BM, bone metastases/bone lesions, HM, haematological malignancy; SRE, skeletal-related event; ST, solid tumour.
Some patients had multiple SREs.
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bone lesions may be being stopped at a point at which ben-
efit could still be derived. At the time of this study, only
one guideline recommended continuing bone-targeted
therapy for more than 2 years because of the continued
risk of SREs (Aapro et al. 2008). Other guidelines did not
advise on optimal treatment duration (Aapro et al. 2008;
Cardoso et al. 2010; Mohler et al. 2010), therefore it may
be difficult for physicians to make decisions on planned
bisphosphonate treatment schedules. More recently, the
International Myeloma Network has recommended zole-
dronic acid should be given continuously to patients with
active multiple myeloma until disease progression or until
a very good or complete response is achieved (Terpos et al.
2013). Similarly, the European Myeloma Network has rec-
ommended continuous treatment with zoledronic acid,
and treatment with pamidronate for up to 2 years (Terpos
et al. 2015). There is still a need for clarification regarding
the optimal duration of bone-targeted therapy in general
for patients with bone metastases resulting from ST
because more recently published guidelines have not
reached a consensus (Van Poznak et al. 2011; European
Association of Urology 2016; European Society for Medi-
cal Oncology 2015; National Comprehensive Cancer Net-
work 2016).
In this study, many patients with bone disease sec-
ondary to malignancies were expected never to receive bis-
phosphonate treatment. Short life expectancy was the
most common reason cited for not treating patients with
bisphosphonates, although over two-thirds of patients
with bone metastases or lesions had a life expectancy of
more than 1 year. Therefore, benefit could be derived from
treatment with bone-targeted agents which can reduce the
risk of SREs and therefore improve the quality of life of
patients (Lipton 2010). More recent guidelines suggest that
patients expected to live for 3 months or longer should be
considered for bone-targeted therapy (Coleman et al.
2014a). It remains unknown whether bisphosphonate
treatment in patients with asymptomatic multiple mye-
loma offers any advantage in the prevention of SREs (Ter-
pos et al. 2013, 2014, 2015).
In this survey, it was noted that treatment with bisphos-
phonates was frequently delayed owing to safety concerns
in patients with bone metastases or lesions secondary to
ST of HM. These concerns included side effects such as
osteonecrosis of the jaw and renal toxicity (Conte & Guar-
neri 2004; Woo et al. 2006). Osteonecrosis of the jaw has
since been identified as being associated with all bone-tar-
geted agents and while the risk remains low, the European
Medicines Agency has recommended the implementation
of updates to product information and the introduction of
patient reminder cards (EMA 2015a). Interestingly, how-
ever, historical data suggest that for most patients, the
benefits of treatment outweigh the associated risks (Cole-
man 2008). In our survey, renal complications were given
as a common reason to avoid administering bisphospho-
nates. Renal morbidity was prevalent in our study, affect-
ing one-third of patients to some degree. The EU approval
in 2010 of the RANK Ligand inhibitor, denosumab, which
has no effect on renal function as its metabolism and elim-
ination follow the immunoglobulin clearance pathways
(von Moos et al. 2013; EMA 2015b), may lead to more
patients receiving and benefiting from bone-targeted ther-
apies given that renal impairment is particularly relevant
in elderly cancer patients (Body et al. 2010; Fizazi et al.
2011). Furthermore, denosumab treatment resulted in a
superior reduction in the risk of SREs compared with zole-
dronic acid in patients with ST and therefore is a more effi-
cacious treatment choice (Henry et al. 2010, 2014;
Stopeck et al. 2010; Fizazi et al. 2011).
Although the results of the present study were generally
consistent across countries, and across malignancy type,
the German data stood out for a number of reasons. First,
patients with ST were younger than in the other countries.
This could be owing to more widespread cancer screening,
leading to diagnosis at a younger age, rather than to differ-
ences in the epidemiology of the cancers. This is supported
by the finding that bone metastases and lesions were dis-
covered more frequently in German patients through rou-
tine screening during follow-up than during staging at
diagnosis. Furthermore, more patients were diagnosed
with a solitary bonemetastasis or lesion and fewer patients
were diagnosed owing to development of pain in Germany
than in the other countries, which suggest that these bone
metastases and lesions were being detected at an earlier
stage. At the time of this study, the German National
Health Service had approved the reimbursement of posi-
tron emission tomography for disease staging and tumour
characterisation in patients with non-small cell lung can-
cer (Buck et al. 2010), which may have promoted a differ-
ent approach to cancer diagnosis in general. Routine bone
scanning in asymptomatic patients (not currently recom-
mended by treatment guidelines) could lead to earlier
detection of bone metastases and lesions, which is a more
proactive attitude to diagnosis and preventive treatment of
SREs inGermany than in other countries.
Although we were unable to collect data on denosumab
use because the survey was conducted before the agent
receivedmarketing authorisation, the results of this patient
chart audit are still relevant to current clinical practice
because disagreements still exist between guideline recom-
mendations and physicians’ opinions relating to optimal
bone care for patients with cancer (Payne et al. 2013; Cole-
10 © 2016 The Authors. European Journal of Cancer Care Published by John Wiley & Sons Ltd.
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man et al. 2014b). Barriers still remain that prevent patients
accessing bisphosphonates, including perceived short life
expectancy and short treatment duration. Although recent
guidelines published after this study was conducted have
evolved, for instance, it is now recommend that patients
expected to live for 3 months or longer should be considered
for bone-targeted therapy (Coleman et al. 2014a), there are
still gaps in the guidelines regarding optimal treatment
duration. Improving screening and diagnostic practices for
bonemetastases and lesions throughout Europe to facilitate
early detection (as seen in Germany) may allow earlier
access to bone-targeted agents so that patients with cancer
can receive the best standard of care.
CONCLUSION
The results from this study highlight some notable differ-
ences in treatment practices between countries as well as
some unexpected findings when the data are considered in
the context of international cancer treatment guidelines.
It is likely that many of the patients who are expected not
to receive bisphosphonates could benefit from this treat-
ment. The number of patients discontinuing treatment
after a short time is also of concern, particularly as these
agents may prevent not only first SREs but also subse-
quent events. Therefore, improving access to treatment
that reduces the risk of SREs could enhance the quality of
life of patients with advanced cancer. This improved
access could be achieved through increased awareness of
both the overall burden of bone metastases and lesions,
and the need to treat patients to prevent SREs, and
improvements in cancer treatment guidelines. It is impor-
tant to breakdown perceived treatment barriers, such as
short life expectancy, and to ensure that guidelines pro-
vide appropriate advice on duration of treatment. The
availability of new bone-targeted agents, with superior
efficacy and no evidence of impact on renal function, may
encourage physicians increase their focus on the manage-
ment of bone involvement from ST and HM.
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APPENDIX 1
SIMPLE QUESTIONNAIRE :
Please report on all cancer patients (solid tumour, NHL, multiple myeloma) meeting the following criteria: 
- Patients with bone metastases / bone lesions
- Patients without bone metastases/ bone lesions (BM/BL) but treated with bisphosphonates (to delay progression to Bone metastases/Bone lesions or to treat for Cancer Treatment Induced Bone Loss (CTIBL)
N° Q.1.Consultation
Q.4.
Cancer Type
Q.5.
Date of initial diagnosis 
of this cancer
Q.7. Solid Tumour/NHL cases:
Date of Re staging to Stage IV/ 
discovery of distant metastases
Q.9.
Patient Status regarding Bisphosphonate treatment for cancer-
related reasons:
Q.10.
Date of next 
consultation
1
|__|__| |__|__| |__|__|
DAY MONTH     YEAR
1
:
….…………………
|__|__| |__|__|
Month Year
|__|__| |__|__|
Month Year Start date of treatment: |__|__| |__|__|
Month       Year
treatment: |__|__| |__|__|
Month      Year
- 3 months
Q.2.
Sex
Q.6.
Stage at the diagnosis 
Q.8.
Bone metastases/Lesions
MALE
FEMALE
(NA for multiple 
Myeloma)
8a. Bone metastases/lesions?
1 Yes
2 No
8b. If yes, Date of diagnosis of 
Bone  Metastases/lesions
|__|__| |__|__|
Month Year
Q.3.
Date of birth
Q9b. If patient is currently receiving bisphosphonates and does not 
have bone metastases/bone lesions, why is s/he treated with 
bisphosphonates?
delay progression to Bone metastases/Bone lesions
treat bone loss due to hormonal cancer treatments (CTIBL= 
cancer treatment induced bone loss)
|__|__| |__|__|
Month Year
N° Q.1.Consultation
Q.4.
Cancer Type
Q.5.
Date of initial diagnosis 
of this cancer
Q.7. Solid Tumour/NHL cases:
Date of Re staging to Stage IV/ 
discovery of distant metastases
Q.9.
Patient Status regarding Bisphosphonate treatment for cancer-
related reasons:
Q.10.
Date of next 
consultation
2
|__|__| |__|__| |__|__|
DAY MONTH     YEAR
1
:
….…………………
|__|__| |__|__|
Month Year
|__|__| |__|__|
Month Year Start date of treatment: |__|__| |__|__|
Month       Year
treatment: |__|__| |__|__|
Month      Year
- 3 months
Q.2.
Sex
Q.6.
Stage at the diagnosis 
Q.8.
Bone metastases/Lesions
MALE
FEMALE
(NA for multiple 
Myeloma)
8a. Bone metastases/lesions?
1 Yes
2 No
8b. If yes, Date of diagnosis of 
Bone  Metastases/lesions
|__|__| |__|__|
Month Year
Q.3.
Date of birth
Q9b. If patient is currently receiving bisphosphonates and does not 
have bone metastases/bone lesions, why is s/he treated with 
bisphosphonates?
delay progression to Bone metastases/Bone lesions
treat bone loss due to hormonal cancer treatments (CTIBL= 
cancer treatment induced bone loss)
|__|__| |__|__|
Month Year
N° Q.1.Consultation
Q.4.
Cancer Type
Q.5.
Date of initial diagnosis 
of this cancer
Q.7. Solid Tumour/NHL cases:
Date of Re staging to Stage IV/ 
discovery of distant metastases
Q.9.
Patient Status regarding Bisphosphonate treatment for cancer-
related reasons:
Q.10.
Date of next 
consultation
3
|__|__| |__|__| |__|__|
DAY MONTH     YEAR
1
:
….…………………
|__|__| |__|__|
Month Year
|__|__| |__|__|
Month Year Start date of treatment: |__|__| |__|__|
Month       Year
treatment: |__|__| |__|__|
Month      Year
- 3 months
Q.2.
Sex
Q.6.
Stage at the diagnosis 
Q.8.
Bone metastases/Lesions
MALE
FEMALE
(NA for multiple 
Myeloma)
8a. Bone metastases/lesions?
1 Yes
2 No
8b. If yes, Date of diagnosis of 
Bone  Metastases/lesions
|__|__| |__|__|
Month Year
Q.3.
Date of birth
Q9b. If patient is currently receiving bisphosphonates and does not 
have bone metastases/bone lesions, why is s/he treated with 
bisphosphonates?
delay progression to Bone metastases/Bone lesions
treat bone loss due to hormonal cancer treatments (CTIBL= 
cancer treatment induced bone loss)
|__|__| |__|__|
Month Year
CENSUS
14 © 2016 The Authors. European Journal of Cancer Care Published by John Wiley & Sons Ltd.
LEBRET ET AL.
APPENDIX 2
DETAILED QUESTIONNAIRE :
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SUPPORTING INFORMATION
Additional Supporting Information may be found online in the supporting information tab for this article:
Table S1. Current cancer treatments at diagnosis, by malignancy type and by country: data from the detailed ques-
tionnaire.
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